British multinational pharmaceutical company GlaxoSmithKline (NYSE: GSK) declared in its last quarterly earnings call that the company’s integration and restructuring programs are on track, and sales are benefiting from recent new product introductions and most products recently acquired.So much so, that the company says it will meet its guidance for 2015… Read More